Ticker > Company >

Ajanta Pharma share price

Ajanta Pharma Ltd.

NSE: AJANTPHARM BSE: 532331 SECTOR: Pharmaceuticals & Drugs  111k   531   55

2,567.80
-17.50 (-0.68%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 2,583.05

Today's Low

₹ 2,544.95

52 Week High

₹ 3,485.75

52 Week Low

₹ 2,022.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

32,074.93 Cr.

Enterprise Value

32,025.21 Cr.

No. of Shares

12.49 Cr.

P/E

34.98

P/B

8.86

Face Value

₹ 2

Div. Yield

1.09 %

Book Value (TTM)

₹  289.81

CASH

49.72 Cr.

DEBT

0 Cr.

Promoter Holding

66.26 %

EPS (TTM)

₹  73.40

Sales Growth

8.84%

ROE

26.09 %

ROCE

33.66%

Profit Growth

13.58 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Ajanta Pharma Ltd.

Met XL Softdrops Sunstop Kamagra Melacare Cinod Feburic Forticord Zaha Ilapro

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.84%
3 Year11.23%
5 Year14.5%

Profit Growth

1 Year13.58%
3 Year8.4%
5 Year15.76%

ROE%

1 Year26.09%
3 Year22.59%
5 Year23.37%

ROCE %

1 Year33.66%
3 Year29.6%
5 Year30.57%

Debt/Equity

0

Price to Cash Flow

30.44

Interest Cover Ratio

257.53

CFO/PAT (5 Yr. Avg.)

0.96

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 66.26 12.61
Dec 2024 66.26 11.17
Sep 2024 66.26 11.17
Jun 2024 66.27 11.57
Mar 2024 66.21 12.26
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 22.59% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.60% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 257.53.
  • The Company has been maintaining an effective average operating margins of 27.08% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -7.42 days.
  • Company has a healthy liquidity position with current ratio of 3.61.

 Limitations

  • The company has shown a poor profit growth of 8.40% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.23% for the Past 3 years.
  • Promoter pledging has increased from 11.17% to 12.61% in 1 quarter.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 926.07 1,077.27 1,128.91 1,101.92 1,013.94
Total Expenditure 698.92 761.44 826 765.59 764.29
Operating Profit 227.15 315.83 302.91 336.33 249.65
Other Income 33.68 28.37 40.34 33.23 17.93
Interest 1.42 0.72 0.73 2.48 0.67
Depreciation 33.47 32.92 33.32 34.93 38.76
Exceptional Items 0 0 0 0 0
Profit Before Tax 225.94 310.56 309.20 332.15 228.15
Tax 63.25 74.53 74.22 79.70 34.72
Profit After Tax 162.69 236.03 234.98 252.45 193.43
Adjusted EPS (Rs) 12.88 18.83 18.75 20.14 15.43

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2,718.59 3,140.64 3,411.27 3,971.12 4,322.04
Total Expenditure 1,801.68 2,249.75 2,711.99 2,851.69 3,117.32
Operating Profit 916.91 890.89 699.28 1,119.43 1,204.72
Other Income 103.57 139.73 132.75 116.48 119.87
Interest 6.90 9.12 5.23 6.80 4.60
Depreciation 111.49 120.96 126.95 132.16 139.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 902.09 900.54 699.85 1,096.95 1,180.06
Tax 226.45 180.68 141.13 289.71 263.17
Net Profit 675.64 719.86 558.72 807.24 916.89
Adjusted EPS (Rs.) 52.07 56.20 44.38 64.12 73.41

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 17.39 17.17 25.27 25.27 25.07
Total Reserves 2,867.59 3,152.01 3,221.18 3,388.30 3,600.24
Borrowings 0 0 0 0 0
Other N/C liabilities 321.18 338.33 272.90 174.17 218.22
Current liabilities 706.28 469.70 907.84 629.19 710.72
Total Liabilities 3,912.44 3,977.21 4,427.19 4,217.44 4,554.25
Assets
Net Block 1,509.89 1,483.91 1,484.01 1,464.89 1,741.96
Capital WIP 108.19 152.86 209.47 256.45 176.27
Intangible WIP 0 0 0 0 0
Investments 17.89 42.99 42.99 37.09 43.13
Loans & Advances 230.52 226.15 134.68 12.97 13.12
Other N/C Assets 19.55 14.29 12.77 13.22 12.56
Current Assets 2,026.40 2,057.01 2,543.27 2,432.82 2,567.21
Total Assets 3,912.44 3,977.21 4,427.19 4,217.44 4,554.25
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 902.09 900.54 699.85 1,096.95 1,180.06
Adjustment 37.07 55.58 79.34 49.31 69.38
Changes in Assets & Liabilities -274.26 -220.31 82.66 -158.63 86.19
Tax Paid -197.91 -193.47 -125.56 -252.28 -281.83
Operating Cash Flow 466.99 542.34 736.29 735.35 1,053.80
Investing Cash Flow -162.68 -66.04 -501.31 105.02 -349.60
Financing Cash Flow -268.90 -457.30 -105.12 -1,047.70 -715.71
Net Cash Flow 35.41 19 129.86 -207.33 -11.51

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 66.21 66.27 66.26 66.26 66.26
aayush m agrawal 0.02 0.02 0.02 0.02 0.02
aayush m agrawal, trustee... 11.31 11.30 11.30 11.30 11.30
gabs investments pvt ltd 10.00 10.08 10.08 10.08 10.08
ganga exports being repre... 2.68 2.68 2.68 2.68 2.68
rajesh m agrawal, trustee... 14.48 14.48 14.47 14.47 14.47
ravi p agrawal 0.23 0.23 0.23 0.23 0.23
ravi p agrawal, trustee r... 13.01 13.01 13.00 13.00 13.00
yogesh m agrawal, trustee... 14.48 14.48 14.47 14.47 14.47
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 33.79 33.73 33.74 33.74 33.74
canara robeco mutual fund... - - - - 1.38
hdfc large and mid cap fu... 1.04 1.13 1.54 1.47 1.25
investor education and pr... - - 0.09 - 0.09
kotak small cap fund 1.24 1.24 1.24 1.24 1.46
llp 0.03 0.03 0.03 0.02 0.02
nippon life india trustee... 2.99 3.04 2.98 2.99 2.84
tata aia life insurance c... 1.65 1.67 1.34 1.24 1.25
uti-flexi cap fund - - - - 2.96
canara robeco mutual fund... - - 1.03 1.09 -
investor education and pr... 0.09 0.09 - 0.09 -
uti flexi cap fund 3.08 3.03 2.95 2.86 -
aditya birla sun life tru... - - 1.05 - -

Annual Reports

Title Link
Annual Report 2024
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
Credit CARE
TYPE AGENCY Link
Research Report By:
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Way2Wealth
Research ICICI Securities Limited

Concalls & Presentations

TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY24
Concall Q3FY24
Concall Q3FY22
Concall Q2FY24
Concall Q1FY24
TYPE QUARTER Link
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY21
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY21
Presentation Q1FY20
Presentation Q3FY20

Company News

Ajanta Pharma Stock Price Analysis and Quick Research Report. Is Ajanta Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ajanta Pharma and its performance over the period of time. Ajanta Pharma stock price today is Rs 2,564.90.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ajanta Pharma cash from the operating activity was Rs 1,053.80 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ajanta Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ajanta Pharma , the EPS growth was 14.49 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ajanta Pharma has OPM of 27.87 % which is a good sign for profitability.
     
  • ROE: Ajanta Pharma have a healthy ROE of 26.09 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ajanta Pharma is Rs 2,564.90. One can use valuation calculators of ticker to know if Ajanta Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Ajanta Pharma
X